CISPLATIN NEUROTOXICITY - THE RELATIONSHIP BETWEEN DOSAGE, TIME, AND PLATINUM CONCENTRATION IN NEUROLOGIC TISSUES, AND MORPHOLOGICAL EVIDENCE OF TOXICITY

被引:296
作者
GREGG, RW
MOLEPO, JM
MONPETIT, VJA
MIKAEL, NZ
REDMOND, D
GADIA, M
STEWART, DJ
机构
[1] OTTAWA REG CANC CTR, ONTARIO CANC TREATMENT & RES FDN, OTTAWA, ONTARIO, CANADA
[2] UNIV OTTAWA, FAC HLTH SCI, OTTAWA K1N 6N5, ONTARIO, CANADA
关键词
D O I
10.1200/JCO.1992.10.5.795
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To identify the major sites of platinum accumulation within neural tissues after treatment with cisplatin and to determine the relationship between cumulative dosage, time, and the development of histopathological and clinical neurotoxicify. Patients and Methods: Twenty-one patients treated antemortem with cisplatin had neural tissue harvested at autopsy. Neural tissues were assayed for platinum and examined for histopathologic evidence of neurotoxicity. The relationship between histopathologic neurotoxicity and various pharmacologic parameters was analyzed. Results: Tissue platinum levels were found to be highest in the dorsal root ganglia and lowest in tissue protected by the blood-brain barrier. For peripheral nerve, dorsal root, and dorsal root ganglia, a linear relationship was observed between platinum levels and cumulative dose. Platinum levels in neural tissue were not observed to decrease with time. Histopathologic toxicity closely matched an index of exposure to platinum (cumulative dose and log of time). Clinical and histopathologic neurotoxicity was found to occur with higher accumulations of platinum, with the highest levels found in patients with clinical evidence of neurotoxicity. Conclusions: The dorsal root ganglia was the most vulnerable neural structure. This is consistent with the clinical presentation of sensory neuropathy in cisplatin neurotoxicity. Central structures of the spinal cord and brain were protected from platinum accumulation. The increasing histopathologic toxicity, with an index of exposure to platinum, suggests that it is retained indefinitely in an actively neurotoxic form. The pharmacologic parameters examined correlate with the development of and are consistent with the clinical and laboratory features of cisplatin neurotoxicity. © 1992 by American Society of Clinical Oncology.
引用
收藏
页码:795 / 803
页数:9
相关论文
共 54 条
[41]   CARBOPLATIN (PARAPLATIN JM8) AND ETOPOSIDE (VP-16) AS 1ST-LINE COMBINATION THERAPY FOR SMALL-CELL LUNG-CANCER [J].
SMITH, IE ;
EVANS, BD ;
GORE, ME ;
VINCENT, MD ;
REPETTO, L ;
YARNOLD, JR ;
FORD, HT .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (02) :185-189
[42]  
STEWART D, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P246
[43]  
STEWART D, 1988, J NEUROPATH EXP NEUR, V47, P312
[44]   RENAL AND HEPATIC CONCENTRATIONS OF PLATINUM - RELATIONSHIP TO CISPLATIN TIME, DOSE, AND NEPHROTOXICITY [J].
STEWART, DJ ;
MIKHAEL, NZ ;
NANJI, AA ;
NAIR, RC ;
KACEW, S ;
HOWARD, K ;
HIRTE, W ;
MAROUN, JA .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (09) :1251-1256
[45]  
STEWART DJ, 1987, P AN M AM SOC CLIN, V6, P40
[46]  
STOTER G, 1979, LANCET, V1, P941
[47]  
TENBOKKEL HWW, 1985, CANCER TREAT REV, V12, P77
[48]   CELLULAR-DISTRIBUTION OF CIS-DIAMMINEDICHLOROPLATINUM(II) DNA-BINDING IN RAT DORSAL-ROOT SPINAL GANGLIA - EFFECT OF THE NEUROPROTECTING PEPTIDE ORG 2766 [J].
TERHEGGEN, PMAB ;
VANDERHOOP, RG ;
FLOOT, BGJ ;
GISPEN, WH .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1989, 99 (02) :334-343
[49]  
THOMPSON SW, 1984, CANCER, V54, P1269, DOI 10.1002/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO
[50]  
2-9